Impacts of the COVID-19 pandemic on healthcare access among patients receiving medication for opioid use disorder
| Autor: | Bryan Hartzler, Sara J. Becker, Julia Yermash, Kimberly R. Yap, Tim Janssen, Elizabeth L. Ball, Bryan R. Garner, Brendan Jacka |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Substance-Related Disorders Short Communication Toxicology Health Services Accessibility 03 medical and health sciences Polysubstance use 0302 clinical medicine Harm Reduction New England Naloxone Opiate Substitution Treatment medicine Syringe service programs Humans Pharmacology (medical) 030212 general & internal medicine Pharmacology Clinical Trials as Topic Harm reduction business.industry COVID-19 Opioid use disorder Healthcare access medicine.disease Latent class model Buprenorphine Opioids Identified patient Psychiatry and Mental health Cross-Sectional Studies Latent Class Analysis Polysubstance dependence Family medicine Female business Methadone 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Drug and Alcohol Dependence |
| ISSN: | 0376-8716 |
| DOI: | 10.1016/j.drugalcdep.2021.108617 |
| Popis: | Background The COVID-19 pandemic significantly altered treatment delivery for opioid treatment programs (OTPs) dispensing medications for opioid use disorder (MOUD). We aimed to identify patterns of substance use among MOUD patients and examine whether COVID-19-related impacts on access to healthcare varied across subgroups. Methods This analysis was embedded within a type 3 hybrid trial that enrolled patients across eight OTPs at the start of the pandemic. Enrolled patients reported on past-30 day use of multiple substances during their baseline assessment. Participants re-contacted in May–July 2020 completed a survey about COVID-19-related impacts on various life domains. Using latent class analysis we identified patient subgroups, and then examined group differences on a set of negative and positive COVID-19 impacts related to healthcare access. Results Of the 188 trial participants, 135 (72 %) completed the survey. Latent class analysis identified three MOUD patient subgroups: minimal use (class probability: 0.25); opioid use (class probability: 0.34); and polysubstance use (class probability: 0.41). Compared to the minimal use group, the polysubstance use group reported increased substance use and difficulty accessing sterile needles, naloxone, and preferred substance. The opioid use group reported increased substance use and difficulty accessing their preferred substance. There were no significant group differences related to accessing routine or specialized healthcare or medication; or paying attention to their health. Conclusions During COVID-19, many MOUD patients reported challenges accessing care, particularly harm reduction services for patients with polysubstance use. Additional efforts, like providing wraparound support, may be necessary to serve the needs of MOUD patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect